International programme seeks innovative health tech solutions

News

Author: Saskia MairPublished: 11 June 2020

Prep: Cook: Serves:

Zambon Open Accelerator 2019 awards ceremony

Open Accelerator, an international programme supporting digital healthcare technologies that improve patient experience, has launched its 2020 ‘Call for Solutions’.

Created by Zcube, the research venture of Italian pharmaceutical company Zambon, the accelerator focuses on four key areas: ‘digital prevention, monitoring and therapeutics’, ‘digital diagnostics’, ‘virtual health’ and ‘clinical trials digitalisation’. Successful applicants will take part in a four-week programme, and could win up to EUR €100,000 seed investment for their project. In response to the Covid-19 pandemic, a ‘Special Challenge’ will be dedicated to new forms of communication in healthcare.

Elena Zambon, creator of the programme said: “Digital solutions have never been such a vital support for patients and caregivers as they have at this time.

“This programme is yet another way in which we are pursuing with conviction our commitment to improving patients’ lives, integrating cure and care with a multidisciplinary approach.”

Submissions are open until 20 July 2020. To find out more about how to apply visit the Open Accelerator website.

For more information on the latest Parkinson’s research please visit the EPDA website.

Diesel exhaust fumes may increase the risk of Parkinson’s, study suggests

Last Month

Next Month

Go Back

Share this story

Comments

Europe

Parkinson Italia launches multi-stakeholder White Book research project

Major new study will help create ‘patient wellbeing scale’

Tom Isaacs president of The Cure Parkinson’s Trust has died

"We're devastated but are focusing on his incredible achievements"

Women and Parkinson’s: menstruation, medication and motherhood

Our podcast shines a light on how women experience the condition

Wearable device for Parkinson’s disease raises $10m in funding

UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…

Does Parkinson’s disease start in the nose?

An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.

Study finds gene therapy may restore effects of Parkinson’s drug

Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

International programme seeks innovative health tech solutions

News

Author: Saskia MairPublished: 11 June 2020

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Europe

Parkinson Italia launches multi-stakeholder White Book research project

Perspectives

Tom Isaacs president of The Cure Parkinson’s Trust has died

Women and Parkinson's

Women and Parkinson’s: menstruation, medication and motherhood

Wearable device for Parkinson’s disease raises $10m in funding

Does Parkinson’s disease start in the nose?

Study finds gene therapy may restore effects of Parkinson’s drug

{title}

Subscribe

International programme seeks innovative health tech solutions

News

Author: Saskia MairPublished: 11 June 2020

Last Month

Next Month

Share this story

Comments

Related articles

Europe

Parkinson Italia launches multi-stakeholder White Book research project

Perspectives

Tom Isaacs president of The Cure Parkinson’s Trust has died

Women and Parkinson's

Women and Parkinson’s: menstruation, medication and motherhood

Wearable device for Parkinson’s disease raises $10m in funding

Does Parkinson’s disease start in the nose?

Study finds gene therapy may restore effects of Parkinson’s drug

{title}

Subscribe

Sign in